Boston Scientific Goes on a Buying Spree
Executive Summary
Just a couple of years ago, the notion that cardiovascular device companies would begin to build broad franchises or platforms would have been unthinkable. Go tell that to Boston Scientific.
You may also be interested in...
How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook
Boston Scientific CEO Jim Tobin, in a series of addresses, defends his company's decision to spend $27.3 billion on Guidant Inc., warts and all. Defying criticism of the deal, Tobin lays out how Boston Scientific management corrected Guidant's problems--and why the new company will thrive.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.